ClinicalTrials.gg
RecruitingNCT07574879Updated Nov 5, 2026

Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:

A Phase 1 interventional study of Eradication of Helcobacter Pylori in Chronic Obstructive Pulmonary Disease (COPD) and With Poitive H Pylori, sponsored by Zagazig University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Zagazig University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt — 26 open to participants now, 28 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Egypt.

Planned enrollment
44th of 53
54 · median 60
Started
2026
with 5 others
Phase 1
3 of 85
1 open now
Primary completion
2026-09
later than 18 of 27 live
Registered
75th of 85
by date

Among the 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt, this one is the 44th largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 18 of the 27 other live ones, and was the 75th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

26 of the 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt, or all of them as a file.
02

Study summary

Helicobacter pylori (HP) is a well-established pathogen responsible for chronic gastritis and peptic ulcer disease. Its presence has been implicated in the development of gastric malignancies such as adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Chronic H. pylori infection is associated with systemic inflammatory responses and various extra gastric diseases, including cardiovascular, metabolic, and neurological disorders. Furthermore, H. pylori infection contributes to gastrointestinal dysbiosis by interacting with gastrointestinal microbiota, which may be involved in gastric carcinogenesis and other systemic disorders. Growing evidence highlights the role of dysbiosis in chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. Emerging epidemiological evidence suggests a potential association between H. pylori infection and respiratory diseases, including COPD. Several observational studies and meta-analyses have found that H. pylori infection in patients with COPD may be associated with systemic inflammatory markers and altered pulmonary function parameters. Despite these associations, the causal mechanisms underlying this relationship remain unclear. Furthermore, it is uncertain whether eradication of H. pylori yields measurable benefits on clinical outcomes in COPD patients. So, Our aim to evaluate changes in symptoms, pulmonary function, and inflammatory markers after H. pylori eradication therapy in the H. pylori-positive COPD patients.

an intervention study (quasi experimental), study will be carried out in the inpatient and outpatient clinics of Chest Department, Faculty of Medicine, Zagazig University hospitals.

Patients included in the study:

well controlled COPD patients attending outpatient clinics for a period of 6 months fulfilling inclusion and exclusion criteria will be included in this study.

Read the detailed description

An interventional study (quasi experimental), this study will be carried out in the inpatient and outpatient clinics of Chest Department, Faculty of Medicine, Zagazig University hospitals.

-Patients included in the study: well controlled COPD patients attending outpatient clinics for a period of 6 months fulfilling inclusion and exclusion criteria will be included in this study.

  • Sample size and selection:

All patients diagnosed with COPD attending the study setting during the specified study period (6 months) will be consecutively screened for Helicobacter pylori infection.

All eligible patients who test positive for H. pylori will be included in the intervention phase and will receive eradication therapy.

Therefore, a consecutive sampling technique will be applied, all available cases during the study period will be recruited. Based on the expected patient flow, approximately 108 COPD patients are anticipated over 6 months, with an estimated H. pylori prevalence of around 50% ((Abdelmagied etal., 2019), yielding about 54 cases for the intervention phase.

All patients will be subjected to the following:

  1. Recruitment of COPD patients based on clinical diagnosis and spirometry.
  2. Collection of baseline demographics, smoking history, comorbidities, exacerbation and hospitalization rate in past year.
  3. Assess H. pylori status using Stool antigen test for H. pylori by using rapid antigen test (lateral flow immune chromatographic test with a monoclonal antibody). It has a positive line to indicate a positive reading accompanied by a control line. The test has been reported sensitivity and specificity (94% and 98% respectively.
  4. Perform COPD Assessment Test (CAT): The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this change over time. The CAT is a standard and validated test containing eight items for the evaluation of the impact of COPD on health status.
  5. Perform baseline spirometry and laboratory markers.
  6. Assess severity of COPD according to GOLD criteria: stage 1 (FEV1 ≥80%), stage 2 (50% ≤FEV1 \<80%), stage 3 (30% ≤FEV1 \<50%), and stage 4 (FEV1 \<30%).
  7. For H. pylori-positive COPD patients: administer standard eradication therapy according to current guidelines (e.g., triple or quadruple therapy with proton pump inhibitor and antibiotics). Confirm eradication at least 4-6 weeks after therapy completion via repeat testing.
  8. Reassess COPD symptoms, lung function, and biomarkers 3months after successful H. pylori eradication.
  9. Follow up H. Pylori-positive COPD patients for 3months by reassessment of COPD symptoms, lung function and biomarkers.
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • With Poitive H Pylori

Keywords

  • Chronic Obstructive Pulmonary disease
  • Helicobacter Pylori
  • eradication therapy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥40 years.
  • Diagnosed with confirmed by spirometry (post-bronchodilator /FVC \< 0.70) and H. pylori positive.
  • Willing to participate and provide consent for testing and follow-up.

Exclusion criteria

Exclusion Criteria:

  • patients with asthma, known peptic ulcers, acute exacerbation of
  • patients who took antibiotics and PPIs within the last month,
  • Patients who took histamine-2-receptor antagonists within the last week or antacid within the last 24 hours a
  • those having H. pylori eradication treatment within the last 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Intervention group

    For H. pylori-positive COPD patients: administer standard eradication therapy according to current guidelines (e.g., triple or quadruple therapy with proton pump inhibitor and antibiotics).

    Drug: Eradication of Helcobacter Pylori

Interventions

  • DrugEradication of Helcobacter Pylori

    Pre- intervention stage:Perform baseline spirometry and laboratory markers, Assess severity of COPD according to GOLD criteria: stage 1 (FEV1 ≥80%), stage 2 (50% ≤FEV1 \<80%), stage 3 (30% ≤FEV1 \<50%), and stage 4 (FEV1 \<30%). * Intervention stage: For H. pylori-positive COPD patients: administer standard eradication therapy according to current guidelines (e.g., triple or quadruple therapy with proton pump inhibitor and antibiotics). Confirm eradication at least 4-6 weeks after therapy completion via repeat testing. * Post intervention: Reassess COPD symptoms, lung function, and biomarkers 3 months after successful H. pylori eradication. Follow up H. Pylori-positive COPD patients for 3months by reassessment of COPD symptoms, lung function and biomarkers.

06

What researchers measure

Primary outcomes

  1. Primary outcome measures

    Reassess symptoms of COPD by COPD Assessment Test (CAT): The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this change over time. The CAT is a standard and validated test containing eight items for the evaluation of the impact of COPD on health status

    Time frame: 3 months

Secondary outcomes

  1. FEV₁ - Volume exhaled in first second

    FEV₁ - Volume exhaled in first second; Unit: L

    Time frame: 3 months after treatment

  2. FVC - Total forced exhaled volume; Unit: L

    FVC - Total forced exhaled volume; Unit: L

    Time frame: 3 months after treatment

  3. FEV₁/FVC Ratio - Airflow limitation index; Unit: %

    FEV₁/FVC Ratio - Airflow limitation index; Unit: %

    Time frame: 3 months after treatment

  4. CRP - Systemic inflammation marker; Unit: mg/L

    CRP - Systemic inflammation marker; Unit: mg/L

    Time frame: 3 months after treatment

  5. PaO₂ - Arterial oxygen pressure; Unit: mmHg

    PaO₂ - Arterial oxygen pressure; Unit: mmHg

    Time frame: 3 months after treatment

  6. PaCO₂ - Arterial carbon dioxide pressure; Unit: mmHg

    PaCO₂ - Arterial carbon dioxide pressure; Unit: mmHg

    Time frame: 3 months after treatment

  7. pH - Arterial acid base status

    pH - Arterial acid base status

    Time frame: 3 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Zagazig University outpatients clinics
    Zagazig, Elsharkia 44, Egypt
    Recruiting
    • Hanaa A Nofal, MD · Contacthanofal@medicine.zu.edu.eg · 01006806873
    • Maha Elsayed Alsadik, MD · Contact01127123248
    • Maha Elsayed Alsadik, MD · Principal investigator
    • Enaam Mohammed Ismail ElSayed, MD · Principal investigator
    • Hanaa A Nofal, MD · Sub investigator
    • Ahmed Attia Abdelmoaty, MD · Sub investigator
08

References and documents

Publications

  • 1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for prevention, diagnosis and management of COPD: 2025 Report. Available on: goldcopd.org/. 2. World Health Organization. Chronic obstructive pulmonary disease (COPD). Available on: www.who.int/news-room/fact -sheets/detail/chronic-obstructive-pulmonary-disease-(copd). 3. Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9:19. 4. Shin DW, Kwon HT, Kang JM, Park JH, Choi HC, Park MS, et al. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J Clin Gastroenterol. 2012;46:840-5. 5. Bakhti SZ, Latifi-Navid S. Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis. BMC Microbiol. 2021;21:258. 6. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135. 7. Li N, Dai Z, Wang Z, Deng Z, Zhang J, Pu J, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res. 2021;22:274. 8. Hufnagl K, Pali-Scholl I, Roth-Walter F, Jensen-Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol. 2020;42:75-93. 9. González-Saitz A, Díez-Manglano J. Helicobacter pylori infection in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. Rev Clin Esp (Barc). 2025 Apr;225(4):193-203. doi: 10.1016/j.rceng.2024.12.004. Epub 2025 Feb 7. 10. Alexandra J, Baumann., D.O. and Staros E: Helicobacter Pylori Antigen Test. e-medicine. medscape. com/ article/2117821-overview. 2014. 11. Jones PW, Harding G, Berry P, Wiklund I, Chen WH and Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J.; 2009, 34(3):648-54. 12. Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylor

Individual participant data

Plan to share: No — Due to privacy of data

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Sep 2026, 6 months.

Of 176 phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
May 8, 2026
StartActual
Mar 1, 2026
Primary completionActual
Sep 30, 2026
CompletionEst.
Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07574879
Lead sponsor
Zagazig University
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Mar 1, 2026
Primary completion
Sep 30, 2026
Completion
Dec 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Hanaa A Nofal, MD
Contact
hanofal@medicine.zu.edu.eg
01006806873
Maha Elsayed Alsadik, MD
Contact
01127123248
Hanaa A Nofal, MD
study director · Faculty of Medicine, Zagazig University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion